Ginkgo biloba prevention trials: More than an ounce of prevention learned

Archives of Neurology

Volumn 66, Issue 5, 2009, Pages 652-654

  Kaye, Jeffrey ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; AMYLOID PROTEIN; BIOLOGICAL MARKER; GINKGO BILOBA EXTRACT;

ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CLINICAL TRIAL; DEMENTIA; DOSE CALCULATION; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; FEASIBILITY STUDY; GENE LOCATION; GINKGO BILOBA; HUMAN; NEUROIMAGING; NONHUMAN; PATIENT COMPLIANCE; PATIENT MONITORING; PREVENTION STUDY; PRIORITY JOURNAL;

ALZHEIMER DISEASE; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; GINKGOLIDES; HUMANS; NEUROPROTECTIVE AGENTS; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT FAILURE;

EID: 66249132308     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2009.47     Document Type: Article

References (20)

1. DeKosky ST, Williamson JD, Fitzpatrick AL, et al; Ginkgo Evaluation of Memory (GEM) Study Investigators. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA. 2008;300(19):2253-2262.
2. Tomlinson BE, Blessed G, Roth M. Observations on the brains of non-demented old people. J Neurol Sci. 1968;7(2):331-356.
3. Seabrook GR, Ray WJ, Shearman M, Hutton M. Beyond amyloid: the next generation of Alzheimer's disease therapeutics. Mol Interv. 2007;7(5):261-270. (Pubitemid 47607486)
4. Vellas B, Andrieu S, Ousset PJ, Ouzid M, Mathiex-Fortunet H; GuidAge Study Group. The GuidAge study: methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761 for prevention of Alzheimer disease in patients over 70 with a memory complaint. Neurology. 2006;67(9)(suppl 3):S6-S11. (Pubitemid 44684670)
5. National Center for Complementary and Alternative Medicine; National Institute on Aging. Ginkgo biloba prevention trial in older individuals. http://grants.nih.gov/grants/guide/rfa-files/RFA-AT-99-001.html. Accessed December 20, 2008.
6. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300(24):2867-2878.
7. Oken BS, Storzbach DM, Kaye JA. The efficacy of ginkgo biloba on cognitive function in Alzheimer's disease. Arch Neurol. 1998;55(11):1409-1415. (Pubitemid 28525500)
8. EGb 761: ginkgo biloba extract, Ginkor. Drugs R D. 2003;4(3):188-193. (Pubitemid 36849666)
9. Stackman RW, Eckenstein F, Frei B, Kulhanek D, Nowlin J, Quinn JF. Prevention of age-related spatial memory deficits in a transgenic mouse model of Alzheimer's disease by chronic Ginkgo biloba treatment. Exp Neurol. 2003;184(1):510-520. (Pubitemid 37444058)
10. Augustin S, Rimbach G, Augustin K, Schliebs R, Wolffram S, Cermak R. Effect of a short- and long-term treatment with Ginkgo biloba extract on amyloid precursor protein levels in a transgenic mouse model relevant to Alzheimer's disease. Arch Biochem Biophys. 2009;481(2):177-182.
11. Vitolo O, Gong B, Cao Z, et al. Protection against beta-amyloid induced abnormal synaptic function and cell death by Ginkgolide J. Neurobiol Aging. 2009;30(2):257-265.
12. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2007;(2):CD003120.
13. Dodge HH, Zitzelberger T, Oken B, Howieson D, Kaye J. A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline. Neurology. 2008;70(19, pt 2):1809-1817.
14. Carlson NE, Moore M, Dame A, et al. Trajectories of brain loss in aging and the development of cognitive impairment. Neurology. 2008;70(11):828-833.
15. Darby D, Maruff P, Collie A, McStephen M. Mild cognitive impairment can be detected by multiple assessments in a single day. Neurology. 2002;59(7):1042-1046.
16. Shankle WR, Romney AK, Hara J, et al. Methods to improve the detection of mild cognitive impairment. Proc Natl Acad Sci U S A. 2005;102(13):4919-4924. (Pubitemid 40471554)
17. Holtzer R, Verghese J, Wang C, Hall CB, Lipton RB. Within-person across-neuropsychological test variability and incident dementia. JAMA. 2008;300(7):823-830.
18. Bender B, Wamboldt FS, O'Connor SL, et al. Measurement of children's asthma medication adherence by self report, mother report, canister weight, and Doser CT. Ann Allergy Asthma Immunol. 2000;85(5):416-421.
19. Hayes TL, Larimer N, Adami A, Kaye J. Medication adherence in healthy elders: small cognitive changes make a big difference. Aging and Health. In press.
20. Live discussion: Leon Thal symposium webinar. Alzheimer Research Forum Web site. http://www.alzforum.org/res/for/journal/detail.asp?liveID=170. Accessed December 20, 2008.